Belimumab is a human monoclonal antibody that targets BAFF and has been approved as an add-on therapy for patients with active, autoantibody-positive SLE, and since recently for the treatment of active LN [11]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.